The Value of Medicines: Treatments for Rheumatoid Arthritis
Reprint from Pfizer World
Today, patients with rheumatoid arthritis generally experience greater health-related quality of life than those diagnosed with the disease 20 years ago.
This is just one of many facts in a Value of Medicines paper on rheumatoid arthritis treatment released recently on Pfizer.com.
The paper is part of a series designed to position Pfizer as a leader on the issue of the value of medicines among key target audiences – policymakers and policy influencers, patient advocacy organizations, and the media - and drive home the message that pharmaceuticals provide incredible value. With topics covering many disease areas and timely topics, these "Value Papers" detail the social and economic value of medicines and rely on published articles, patient stories, and infographics to illustrate the impact that medicines have on public health and a health care system's economy.
Read the Value of Medicines paper on rheumatoid arthritis treatment and other Value Papers here.